NCT06137768已完成2 期
A Trial to Evaluate the Efficacy and Safety of HRS-5965 Tablets in Primary IgA Nephropathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 123
- 试验地点
- 1
- 主要终点
- Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baseline
研究概览
简要总结
The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide a written informed consent；
- •Weight ≥35 kg, Body mass index (BMI) < 37.5kg /m2;
- •Primary IgA nephropathy was confirmed by renal biopsy within 5 years;
- •24-UPE≥ 0.75g /24h, or UPCR≥ 0.8g/g at screening and prior to randomization;
- •eGFR≥30 ml/min/1.73m2 at screening and prior to randomization; (CKD-EPI formula)
- •A fertile female subject or a male subject whose partner is a fertile female, who has not had a fertility, sperm/egg donation plan from the signing of the informed consent to 1 month after the last dose, and voluntarily takes effective contraceptive measures (including the partner);
- •Receiving optimal supportive therapy including RAS blockers for 12 weeks and stabilizing the dose for at least 4 weeks after reaching the maximum recommended dose or the maximum tolerated dose prior to randomization;
排除标准
- •Allergic to any RAS blockers, investigational products, or components as evaluated by the investigator;
- •Patients with secondary IgA nephropathy as determined by the investigator;
- •IgA nephropathy with rapid decline of renal function; Kidney pathology indicated that more than 50% of the glomerulus had large crescent body formation, which may affect the study results; Tubule atrophy - interstitial fibrosis of more than 50%;
- •Patients with a history of immunodeficiency disease; Or in combination with other systemic diseases likely to cause proteinuria;
- •Have any organ transplant;
- •Patients with chronic recurrent infections within 1 year prior to screening, such as liver abscess and pyelonephritis; Or subjects with active infection who requiring intravenous antibiotic therapy within 2 weeks prior to randomization;
- •Patients with a history of malignant neoplasms;
- •Patients with a history of severe trauma or major surgery within 12 weeks prior to screening, or who plan to undergo surgery during the study period;
- •Patients with a history of blood donation or a history of severe blood loss (≥400 mL blood loss) within 12 weeks prior to screening, or who have received blood transfusions within 12 weeks prior to screening;
- •The presence of a disease or medical condition determined by the investigator might affect drug absorption, distribution, metabolism, and excretion;
- •As determined by the investigator, the subject has any of the following: progression or recovery of a disease;
- •Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), or total bilirubin exceeding 3 times the upper limit of normal (ULN) at screening;
- •Participants who have participated in a clinical trial of any drug or medical device within 12 weeks prior to randomization and are expected to have residual effects of the investigational treatment (as determined by the investigator), or who were within the follow-up period of a clinical study, or within 5 half-lives of the investigational drug, or within 30 days (whichever is older) before screening;
- •Women who are pregnant or breastfeeding;
- •A history of drug abuse;
- •Any physical or mental illness or condition that, as determined by the investigator, is likely to increase the risk of the study, affect the subject's adherence to the protocol, or prevent the subject from completing the study.
研究组 & 干预措施
Treatment group A: HRS-5965; high dose
Experimental
干预措施: HRS-5965 (Drug)
Treatment group B: HRS-5965; medium dose
Experimental
干预措施: HRS-5965 (Drug)
Treatment group C: HRS-5965; low dose
Experimental
干预措施: HRS-5965 (Drug)
Treatment group E
Experimental
干预措施: HRS-5965 (Drug)
Treatment group D: Placebo.
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baseline
时间窗: Baseline and Week 12
次要结局
- Ratio of Urinary protein to creatinine ratio and Urinary albumin to creatinine ratio to baseline(up to Week 24)
- Change from baseline of estimated glomerular filtration rate（eGFR）(up to Week 24)
- Ratio of 24-hour Urinary protein excretion（UPE） to baseline(up to Week 24)
- Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baseline(up to Week 24)
- Change from baseline of serum creatinine(up to Week 24)
- Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baseline(Baseline and Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of HRS-5965 in Healthy Subjects and Subjects With Renal InsufficiencyGlomerulonephritisNCT05505955Chengdu Suncadia Medicine Co., Ltd.83
招募中
1 期
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerProstate CancerNCT06568094Jiangsu HengRui Medicine Co., Ltd.100
已完成
1 期
Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy SubjectsType 2 DiabetesNCT06132204Shandong Suncadia Medicine Co., Ltd.16
已完成
1 期
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic ImpairmentComplement Mediated Primary or Secondary Glomerular DiseasesNCT06674915Chengdu Suncadia Medicine Co., Ltd.24
进行中（未招募）
1 期
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05781048Jiangsu HengRui Medicine Co., Ltd.56